Dr Linda Mileshkin

Honorary Associate
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone 03 9656 1697

Map

Selected grants

2018

  • ICON9: An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy; Mileshkin L; University College London/Research Support.

2016

  • ICON9: A phase 3 randomised trial of cediranib and olaparib maintenance in patients with relapsed platinum sensitive ovarian cancer; Mileshkin L, Brand A, Ledermann J, Rischin D, Beale P, Quinn M, Coward J, Viney R, Martyn J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2013

  • A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK trial; Mileshkin L, Narayan K, Rischin D, Quinn M, Friedlander M, Moore K, Kitchener H, Shrivastava S, Martyn J, Small Jnr W; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • PORTEC-3 - the role of adjuvant chemotherapy in high-risk endometrial cancer; Mileshkin L, Quinn M, Khaw P, Stockler M, Brand A, Martyn J, Sjoquist K, Creutzberg C; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • de Boer, S., Powell, M., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P., Ledermann, J., Do, V., Khaw, P., et al (2018). Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology, 19(3), 295-309. [More Information]
  • Friedlander, M., Shannon, C., Goh, J., Scott, C., Mileshkin, L. (2018). Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib. Asia-Pacific Journal of Clinical Oncology, 14(6), 459-464. [More Information]
  • Karikios, D., Mileshkin, L., Martin, A., Ferraro, D., Stockler, M. (2017). Discussing and prescribing expensive unfunded anticancer drugs in Australia. ESMO Open, 2(2), 1-7. [More Information]
  • Bonaventura, A., O'Connell, R., Mapagu, C., Beale, P., McNally, O., Mileshkin, L., Grant, P., Hadley, A., Goh, J., Sjoquist, K., Martyn, J., deFazio, A., et al (2017). Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer. International Journal of Gynecological Cancer, 27(5), 900-906. [More Information]
  • Karapetis, C., Guccione, L., Tattersall, M., Gooden, H., Vajdic, C., Lambert, S., Robotin, M., Mileshkin, L., Schofield, P. (2017). Perceptions of cancer of unknown primary site: a national survey of Australian medical oncologists. Internal Medicine Journal, 47(4), 408-414. [More Information]
  • Lee, Y., Kroon, R., Koczwara, B., Haines, I., Francis, K., Millward, M., Kefford, R., Olver, I., Mileshkin, L. (2017). Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia. Internal Medicine Journal, 47(8), 888-893. [More Information]
  • Bergin, R., Hocking, A., Robinson, T., Kabel, D., Mileshkin, L., Juraskova, I., Bernshaw, D., Aranda, S., Schofield, P. (2016). Continuing variation and barriers to nurse-led vaginal dilator education for women with gynaecological cancer receiving radiotherapy. European Journal of Oncology Nursing, 24, 20-21. [More Information]
  • Bergin, R., Grogan, S., Bernshaw, D., Juraskova, I., Penberthy, S., Mileshkin, L., Krishnasamy, M., Hocking, A., Aranda, S., Schofield, P. (2016). Developing an evidence-based, nurse-led psychoeducational intervention with peer support in gynecologic oncology. Cancer Nursing, 39(2), E19-E30. [More Information]
  • Blinman, P., Mileshkin, L., Khaw, P., Goss, G., Johnson, C., Capp, A., Brooks, S., Wain, G., Kolodziej, I., Veillard, A., O'Connell, R., Stockler, M., et al (2016). Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: An ANZGOG substudy of the PORTEC-3 intergroup randomised trial. British Journal of Cancer, 115(10), 1179-1185. [More Information]
  • Martyn, J., Roncolato, F., Willson, M., Lindemann, K., Mileshkin, L. (2016). PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database of Systematic Reviews, 2016 (4), 1-10. [More Information]
  • Jameson, M., McNamara, J., Bailey, M., Metcalfe, P., Holloway, L., Foo, K., Do, V., Mileshkin, L., Creutzberg, C., Khaw, P. (2016). Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. Journal of Medical Imaging and Radiation Oncology, 60(4), 554-559. [More Information]
  • Lakhanpal, R., Yoong, J., Joshi, S., Yip, D., Mileshkin, L., Marx, G., Dunlop, T., Hovey, E., Della Fiorentina, S., Venkateswaran, L., Tattersall, M., et al (2015). Geriatric assessment of older patients with cancer in Australia-A multicentre audit. Journal of Geriatric Oncology, 6(3), 185-193. [More Information]
  • Chim, L., Salkeld, G., Stockler, M., Mileshkin, L. (2015). Weighing up the benefits and harms of a new anti-cancer drug: a survey of Australian oncologists. Internal Medicine Journal, 45(8), 834-842. [More Information]
  • Au-Yeung, G., Webb, P., deFazio, A., Feredaye, S., Bressel, M., Mileshkin, L. (2014). Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecologic Oncology, 133(1), 16-22. [More Information]
  • Schofield, P., Juraskova, I., Bergin, R., Gough, K., Mileshkin, L., Krishnasamy, M., White, K., Bernshaw, D., Penberthy, S., Aranda, S. (2013). A nurse- and peer-led support program to assist women in gynaecological oncology receiving curative radiotherapy, the PeNTAGOn study (peer and nurse support trial to assist women in gynaecological oncology): study protocol for a randomised controlled trial. Trials, 14(1), 1-11. [More Information]
  • Collins, I., Roberts-Thomson, R., Faulkner, D., Rischin, D., Friedlander, M., Mileshkin, L. (2011). Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls. International Journal of Gynecological Cancer, 21(7), 1213-1218. [More Information]

2018

  • de Boer, S., Powell, M., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P., Ledermann, J., Do, V., Khaw, P., et al (2018). Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology, 19(3), 295-309. [More Information]
  • Friedlander, M., Shannon, C., Goh, J., Scott, C., Mileshkin, L. (2018). Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib. Asia-Pacific Journal of Clinical Oncology, 14(6), 459-464. [More Information]

2017

  • Karikios, D., Mileshkin, L., Martin, A., Ferraro, D., Stockler, M. (2017). Discussing and prescribing expensive unfunded anticancer drugs in Australia. ESMO Open, 2(2), 1-7. [More Information]
  • Bonaventura, A., O'Connell, R., Mapagu, C., Beale, P., McNally, O., Mileshkin, L., Grant, P., Hadley, A., Goh, J., Sjoquist, K., Martyn, J., deFazio, A., et al (2017). Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer. International Journal of Gynecological Cancer, 27(5), 900-906. [More Information]
  • Karapetis, C., Guccione, L., Tattersall, M., Gooden, H., Vajdic, C., Lambert, S., Robotin, M., Mileshkin, L., Schofield, P. (2017). Perceptions of cancer of unknown primary site: a national survey of Australian medical oncologists. Internal Medicine Journal, 47(4), 408-414. [More Information]
  • Lee, Y., Kroon, R., Koczwara, B., Haines, I., Francis, K., Millward, M., Kefford, R., Olver, I., Mileshkin, L. (2017). Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia. Internal Medicine Journal, 47(8), 888-893. [More Information]

2016

  • Bergin, R., Hocking, A., Robinson, T., Kabel, D., Mileshkin, L., Juraskova, I., Bernshaw, D., Aranda, S., Schofield, P. (2016). Continuing variation and barriers to nurse-led vaginal dilator education for women with gynaecological cancer receiving radiotherapy. European Journal of Oncology Nursing, 24, 20-21. [More Information]
  • Bergin, R., Grogan, S., Bernshaw, D., Juraskova, I., Penberthy, S., Mileshkin, L., Krishnasamy, M., Hocking, A., Aranda, S., Schofield, P. (2016). Developing an evidence-based, nurse-led psychoeducational intervention with peer support in gynecologic oncology. Cancer Nursing, 39(2), E19-E30. [More Information]
  • Blinman, P., Mileshkin, L., Khaw, P., Goss, G., Johnson, C., Capp, A., Brooks, S., Wain, G., Kolodziej, I., Veillard, A., O'Connell, R., Stockler, M., et al (2016). Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: An ANZGOG substudy of the PORTEC-3 intergroup randomised trial. British Journal of Cancer, 115(10), 1179-1185. [More Information]
  • Martyn, J., Roncolato, F., Willson, M., Lindemann, K., Mileshkin, L. (2016). PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database of Systematic Reviews, 2016 (4), 1-10. [More Information]
  • Jameson, M., McNamara, J., Bailey, M., Metcalfe, P., Holloway, L., Foo, K., Do, V., Mileshkin, L., Creutzberg, C., Khaw, P. (2016). Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. Journal of Medical Imaging and Radiation Oncology, 60(4), 554-559. [More Information]

2015

  • Lakhanpal, R., Yoong, J., Joshi, S., Yip, D., Mileshkin, L., Marx, G., Dunlop, T., Hovey, E., Della Fiorentina, S., Venkateswaran, L., Tattersall, M., et al (2015). Geriatric assessment of older patients with cancer in Australia-A multicentre audit. Journal of Geriatric Oncology, 6(3), 185-193. [More Information]
  • Chim, L., Salkeld, G., Stockler, M., Mileshkin, L. (2015). Weighing up the benefits and harms of a new anti-cancer drug: a survey of Australian oncologists. Internal Medicine Journal, 45(8), 834-842. [More Information]

2014

  • Au-Yeung, G., Webb, P., deFazio, A., Feredaye, S., Bressel, M., Mileshkin, L. (2014). Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecologic Oncology, 133(1), 16-22. [More Information]

2013

  • Schofield, P., Juraskova, I., Bergin, R., Gough, K., Mileshkin, L., Krishnasamy, M., White, K., Bernshaw, D., Penberthy, S., Aranda, S. (2013). A nurse- and peer-led support program to assist women in gynaecological oncology receiving curative radiotherapy, the PeNTAGOn study (peer and nurse support trial to assist women in gynaecological oncology): study protocol for a randomised controlled trial. Trials, 14(1), 1-11. [More Information]

2011

  • Collins, I., Roberts-Thomson, R., Faulkner, D., Rischin, D., Friedlander, M., Mileshkin, L. (2011). Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls. International Journal of Gynecological Cancer, 21(7), 1213-1218. [More Information]

To update your profile click here. For support on your academic profile contact .